Ready-to-use oxygen gradient microplates for customized in vitro assays for the phenotypic and functional characterization of primary macrophages in immuno-oncology drug development

Presented by: Christoph Schifflers, Martijn Vlaming, Emmanuelle Sidot, Jezabel Lefèvre, Ellen Boelen, Enrico Grassilli (InSimili), Stefania Rapino (InSimili), Marco Malferrari (InSimili) and Sofie Pattyn

Presented at: American Association for Cancer Research (AACR) Annual Meeting, April 25-30, 2025, Chicago, IL

Oxygen level fluctuations in the tumor microenvironment can alter the phenotype and function of cancer cells and tumor-infiltrating immune cells, such as macrophages and T cells. For the functional evaluation of immuno-oncology drug candidates, it is important to consider the effects of varying O2 concentrations. Modeling this layer of functional complexity of the tumor microenvironment typically requires the use of animal models or tumoroid systems, which can be complex to establish, time-consuming and expensive. InSimili developed a technology providing ready-to-use microplates that model spatially controlled O2 levels. Combining this technology with IQVIA Laboratories’ highly optimized in vitro assays using high-quality primary immune cells can provide a useful tool with improved predictive value for the cost-effective functional characterization and lead selection of new immuno-oncology drug candidates.

Complete the form below to access this scientific poster.